Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Targeting bile-acid signalling for metabolic diseases
Access 24/7 support from bariatric specialists for questions between appointments
)
In the phase 3 REDEFINE 1 trial, the combination of cagrilintide and semaglutide yielded a mean 20% reduction in body weight over 68 weeks in adults with overweight or obesity, significantly outperforming placebo and either agent alone
(4) systematic reviews without meta-analyses
US$ 24.20
US$ 24.93
US$ 20.40
US$ 23.91
US$ 21.62
US$ 27.05
US$ 21.41
US$ 23.69
